NAV

Enzalutamide

Identification

Summary

Enzalutamideis a second-generation androgen receptor inhibitor used to treat castration-resistant prostate cancer and metastatic castration-sensitive prostate cancer.

Brand Names
Xtandi
Generic Name
Enzalutamide
DrugBank Accession Number
DB08899
Background

Enzalutamide is an androgen receptor (AR) inhibitor for the treatment of castration-resistant prostate cancer (CRPC), both metastatic and non-metastatic.8It is a second-generation antiandrogen agent that the FDA approved on August 31, 2012.8,7Although androgen deprivation therapy (ADT) is the first-line treatment of prostate cancer and remission can be achieved, arising resistance is inevitable, becoming castration-resistant prostate cancer.7Until recently, docetaxel is the only treatment available for metastatic CRPC; however, AR inhibitors have been developed for more targeted therapy, although first-generation AR inhibitors like bicalutamide did not substantially increase the survival rate.7Second-generation such as enzalutamide is more efficacious due to a higher affinity to AR and no partial agonist activity compared to bicalutamide.7,1

Due to a favorable pharmacological profile, a phase 1 study of enzalutamide was initiated in July 2007. Compared to the average time of 10 to 15 years for a drug to go from pre-clinical to clinical studies, enzalutamide was developed relatively rapidly.7

Type
Small Molecule
Groups
Approved
Structure
 3D
Similar Structures
Weight
Average: 464.436
Monoisotopic: 464.093009286
Chemical Formula
C21H16F4N4O2S
Synonyms
  • Enzalutamida
  • Enzalutamide
External IDs
  • MDV 3100
  • MDV-3100
  • MDV3100

Pharmacology

Indication

Enzalutamide is indicated for the treatment of castration-resistant prostate cancer and metastatic castration-sensitive prostate cancer.8

Reduce drug development failure rates
Build, train, & validate machine-learning models
with evidence-based and structured datasets.
See how
Build, train, & validate predictive machine-learning models with structured datasets.
See how
Associated Conditions
Contraindications & Blackbox Warnings
Avoid life-threatening adverse drug events
Improve clinical decision support with information oncontraindications & blackbox warnings, population restrictions, harmful risks, & more.
Learn more
Avoid life-threatening adverse drug events & improve clinical decision support.
Learn more
Pharmacodynamics

Enzalutamide is a second-generation antiandrogen that blocks the activity of androgen and androgen receptor (AR) in prostate cancer. AR activity and prostate cancer progression are closely related due to the normal physiology of prostate cells, providing the rationale for androgen deprivation therapy (ADT).4However, resistance will eventually arise after the commencement of ADT in 2-3 years due to the accumulation of mutations, including constitutively active mutation, AR overexpression, and changes in AR splicing variants.5,1Enzalutamide was therefore designed to exploit these mutations.3In vitro experiments in human prostate cancer cell line VCaP showed that enzalutamide can suppress cell growth and induce apoptosis while other antiandrogens like bicalutamide did not.3

Clinical trials on prostate cancer patients indicated that enzalutamide can lead to a decrease in serum PSA for at least 12 weeks, although this response can be short-lived and thus resulting in enzalutamide resistance.6,3Patients receiving enzalutamide also had a 37% decreased in the risk of death compared to placebo.2

Mechanism of action

Enzalutamide is a competitive androgen receptor (AR) inhibitor that has a threefold inhibition on the androgen signaling pathway without significant AR agonist activity.9,1It inhibits androgen binding to its receptor, androgen receptor nuclear translocation, and subsequent interaction with chromosomal DNA to upregulate oncogenes.1,2Enzalutamide binds to the AR with 5 to 8-fold greater affinity than first-generation antiandrogens such as bicalutamide and only 2-3 fold reduced affinity than the natural ligand dihydrotestosterone.3Molecular docking showed that enzalutamide binds to the ligand binding domain of the AR distinctive from that of bicalutamide.1

Target Actions Organism
AAndrogen receptor
inhibitor
 Humans
Absorption

平均最高温度是1小时(0.5到3小时)following a single 160 mg dose of capsules and 2 hours (0.5 to 6 hours) following a single 160 mg dose of tablets.9Enzalutamide achieves steady-state by Day 28 and its AUC accumulates approximately 8.3-fold relative to a single dose. At steady-state, the mean (%CV) maximum concentration (Cmax) for enzalutamide and N-desmethyl enzalutamide is 16.6 µg/mL (23%) and 12.7 µg/mL (30%), respectively, and the mean (%CV) minimum concentrations (Cmin) are 11.4 µg/mL (26%) and 13.0 µg/mL (30%), respectively.9

Volume of distribution

The mean (%CV) volume of distribution after a single oral dose is 110 L (29%).9

Protein binding

Enzalutamide is 97% to 98% bound to plasma proteins, primarily albumin. N-desmethyl enzalutamide is 95% bound to plasma proteins.9

Metabolism

Enzalutamide is metabolized by CYP2C8 and CYP3A4. CYP2C8 is primarily responsible for the formation of the active metabolite (N-desmethyl enzalutamide). Carboxylesterase 1 metabolizes N-desmethyl enzalutamide and enzalutamide to the inactive carboxylic acid metabolite.9

Hover over products below to view reaction partners

Route of elimination

Enzalutamide is primarily eliminated by hepatic metabolism. 71% of the dose is recovered in urine (including only trace amounts of enzalutamide and N-desmethyl enzalutamide), and 14% is recovered in feces (0.4% of the dose as unchanged enzalutamide and 1% as N-desmethyl enzalutamide).11

Half-life

The mean terminal half-life (t1/2) for enzalutamide in patients after a single oral dose is 5.8 days (range 2.8 to 10.2 days). Following a single 160 mg oral dose of enzalutamide in healthy volunteers, the mean terminal t1/2 for N-desmethyl enzalutamide is approximately 7.8 to 8.6 days.9

间隙

The mean apparent clearance (CL/F) of enzalutamide after a single dose is 0.56 L/h (0.33 to 1.02 L/h).9

Adverse Effects
Improve decision support & research outcomes
With structured adverse effects data, including:blackbox warnings, adverse reactions, warning & precautions, & incidence rates.
Learn more
Improve decision support & research outcomes with our structured adverse effects data.
Learn more
Toxicity

In an embryo-fetal developmental toxicity study in mice, enzalutamide caused developmental toxicity when administered at oral doses of 10 or 30 mg/kg/day throughout the period of organogenesis (gestational days 6-15). Findings included embryo-fetal lethality (increased post-implantation loss and resorptions) and decreased anogenital distance at ≥ 10 mg/kg/day, and cleft palate and absent palatine bone at 30 mg/kg/day. Doses of 30 mg/kg/day caused maternal toxicity. The doses tested in mice (1, 10, and 30 mg/kg/day) resulted in systemic exposures (AUC) of approximately 0.04, 0.4, and 1.1 times, respectively, the exposures in patients. Enzalutamide did not cause developmental toxicity in rabbits when administered throughout the period of organogenesis (gestational days 6-18) at dose levels up to 10 mg/kg/day (approximately 0.4 times the exposures in patients based on AUC).9

在怀孕的大鼠的药代动力学研究single oral 30 mg/kg enzalutamide administration on gestation day 14, enzalutamide and/or its metabolites were present in the fetus at a Cmax that was approximately 0.3 times the concentration found in maternal plasma and occurred 4 hours after administration.9

Based on animal studies, XTANDI may impair fertility in males of reproductive potential. Advise male patients with female partners of reproductive potential to use effective contraception during treatment and for 3 months after the last dose of XTANDI.9

The most common adverse reactions (≥ 5%) are asthenia/fatigue, back pain, diarrhea, arthralgia, hot flush, peripheral edema, musculoskeletal pain, headache, upper respiratory infection, muscular weakness, dizziness, insomnia, lower respiratory infection, spinal cord compression and cauda equina syndrome, hematuria, paresthesia, anxiety, and hypertension.9

Pathways
Not Available
Pharmacogenomic Effects/ADRsBrowse all" title="" id="snp-actions-info" class="drug-info-popup" href="javascript:void(0);">
Not Available

Interactions

Drug InteractionsLearn More" title="" id="structured-interactions-info" class="drug-info-popup" href="javascript:void(0);">
This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
Drug Interaction
Integrate drug-drug
interactions in your software
1,2-Benzodiazepine The serum concentration of 1,2-Benzodiazepine can be decreased when it is combined with Enzalutamide.
Abacavir Abacavir may decrease the excretion rate of Enzalutamide which could result in a higher serum level.
Abametapir The serum concentration of Enzalutamide can be increased when it is combined with Abametapir.
Abatacept The metabolism of Enzalutamide can be increased when combined with Abatacept.
Abemaciclib The serum concentration of Abemaciclib can be decreased when it is combined with Enzalutamide.
Abiraterone The metabolism of Abiraterone can be increased when combined with Enzalutamide.
Abrocitinib The serum concentration of Abrocitinib can be decreased when it is combined with Enzalutamide.
Acalabrutinib The serum concentration of Acalabrutinib can be decreased when it is combined with Enzalutamide.
Aceclofenac Aceclofenac may decrease the excretion rate of Enzalutamide which could result in a higher serum level.
Acemetacin Acemetacin may decrease the excretion rate of Enzalutamide which could result in a higher serum level.
Identify potential medication risks
Easily compare up to 40 drugs with our drug interaction checker.
Get severity rating, description, and management advice.
Learn more
Food Interactions
  • Avoid St. John's Wort. This herb induces the CYP3A4 metabolism of enzalutamide and may reduce its serum concentration.
  • Take with or without food.

Products

Drug product information from 10+ global regions
Our datasets provide approved product information including:
dosage, form, labeller, route of administration, and marketing period.
Access now
Access drug product information from over 10 global regions.
Access now
Brand Name Prescription Products
Name Dosage Strength Route Labeller Marketing Start Marketing End Region Image
Xtandi Capsule 40 mg/1 Oral Astellas Pharma US, Inc. 2012-08-31 Not applicable US flag
Xtandi Tablet 40 mg/1 Oral Astellas Pharma US, Inc. 2020-08-04 Not applicable US flag
Xtandi Tablet 80 mg/1 Oral Astellas Pharma US, Inc. 2020-08-04 Not applicable US flag
Xtandi Tablet, film coated 40 mg Oral Astellas Pharma Europe Bv 2020-12-16 Not applicable EU flag
Xtandi Tablet, film coated 80 mg Oral Astellas Pharma Europe Bv 2020-12-16 Not applicable EU flag
Xtandi Capsule 40 mg/1 Oral Astellas Pharma US, Inc. 2012-08-31 Not applicable US flag
Xtandi Tablet 40 mg/1 Oral Astellas Pharma US, Inc. 2020-08-04 Not applicable US flag
Xtandi Capsule 40 mg Oral Astellas Pharma Europe Bv 2016-09-08 Not applicable EU flag
Xtandi Capsule 40 mg Oral Astellas Pharma Inc 2013-06-07 Not applicable Canada flag

Categories

ATC Codes
L02BB04 — Enzalutamide
Drug Categories
Chemical TaxonomyProvided byClassyfire
Description
This compound belongs to the class of organic compounds known as phenylimidazolidines. These are polycyclic compounds containing an imidazoline substituted by a phenyl group.
Kingdom
Organic compounds
Super Class
Organoheterocyclic compounds
Class
Azolidines
Sub Class
Imidazolidines
Direct Parent
Phenylimidazolidines
Alternative Parents
Trifluoromethylbenzenes/2-halobenzoic acids and derivatives/Alpha amino acids and derivatives/N-phenylthioureas/Benzamides/Benzoyl derivatives/Benzonitriles/Fluorobenzenes/Aryl fluorides/Imidazolidinones
show 11 more
Substituents
2-halobenzoic acid or derivatives/Alkyl fluoride/Alkyl halide/Alpha-amino acid or derivatives/Aromatic heteromonocyclic compound/Aryl fluoride/Aryl halide/Azacycle/Benzamide/Benzenoid
show 29 more
Molecular Framework
Aromatic heteromonocyclic compounds
External Descriptors
benzamides, nitrile, imidazolidinone, monofluorobenzenes, (trifluoromethyl)benzenes, thiocarbonyl compound (CHEBI:68534)
Affected organisms
  • Humans and other mammals

Chemical Identifiers

UNII
93T0T9GKNU
CAS number
915087-33-1
InChI Key
WXCXUHSOUPDCQV-UHFFFAOYSA-N
InChI
InChI=1S/C21H16F4N4O2S/c1-20(2)18(31)28(12-5-4-11(10-26)15(8-12)21(23,24)25)19(32)29(20)13-6-7-14(16(22)9-13)17(30)27-3/h4-9H,1-3H3,(H,27,30)
IUPAC Name
4-{3-[4-cyano-3-(trifluoromethyl)phenyl]-5,5-dimethyl-4-oxo-2-sulfanylideneimidazolidin-1-yl}-2-fluoro-N-methylbenzamide
SMILES
CNC(=O)C1=C(F)C=C(C=C1)N1C(=S)N(C(=O)C1(C)C)C1=CC=C(C#N)C(=C1)C(F)(F)F

References

General References
  1. Schalken J, Fitzpatrick JM: Enzalutamide: targeting the androgen signalling pathway in metastatic castration-resistant prostate cancer. BJU Int. 2016 Feb;117(2):215-25. doi: 10.1111/bju.13123. Epub 2015 Jun 6. [文章]
  2. Saad F: Evidence for the efficacy of enzalutamide in postchemotherapy metastatic castrate-resistant prostate cancer. Ther Adv Urol. 2013 Aug;5(4):201-10. doi: 10.1177/1756287213490054. [文章]
  3. Tran C, Ouk S, Clegg NJ, Chen Y, Watson PA, Arora V, Wongvipat J, Smith-Jones PM, Yoo D, Kwon A, Wasielewska T, Welsbie D, Chen CD, Higano CS, Beer TM, Hung DT, Scher HI, Jung ME, Sawyers CL: Development of a second-generation antiandrogen for treatment of advanced prostate cancer. Science. 2009 May 8;324(5928):787-90. doi: 10.1126/science.1168175. Epub 2009 Apr 9. [文章]
  4. Heinlein CA, Chang C: Androgen receptor in prostate cancer. Endocr Rev. 2004 Apr;25(2):276-308. doi: 10.1210/er.2002-0032. [文章]
  5. Fujita K, Nonomura N: Role of Androgen Receptor in Prostate Cancer: A Review. World J Mens Health. 2019 Sep;37(3):288-295. doi: 10.5534/wjmh.180040. Epub 2018 Sep 10. [文章]
  6. Tan MH, Li J, Xu HE, Melcher K, Yong EL: Androgen receptor: structure, role in prostate cancer and drug discovery. Acta Pharmacol Sin. 2015 Jan;36(1):3-23. doi: 10.1038/aps.2014.18. Epub 2014 Jun 9. [文章]
  7. Menon MP, Higano CS: Enzalutamide, a second generation androgen receptor antagonist: development and clinical applications in prostate cancer. Curr Oncol Rep. 2013 Apr;15(2):69-75. doi: 10.1007/s11912-013-0293-9. [文章]
  8. FDA Approved Drug Products: Xtandi (enzalutamide) capsules/tablets for oral use [Link]
  9. FDA Approved Drug Products: Xtandi (enzalutamide) capsules/tablets for oral use 2022 [Link]
  10. Health Canada Approved Drug Products: Xtandi (enzalutamide) capsules/tablets for oral use 2022 [Link]
  11. Enzalutamide FDA label [Link]
Human Metabolome Database
HMDB0251831
KEGG Drug
D10218
PubChem Compound
15951529
PubChem物质
175427141
ChemSpider
13093347
BindingDB
50425732
RxNav
1307298
ChEBI
68534
ChEMBL
CHEMBL1082407
ZINC
ZINC000034806477
RxList
RxList Drug Page
Drugs.com
Drugs.com Drug Page
Wikipedia
Enzalutamide
FDA label
Download (393 KB)
MSDS
Download (89.7 KB)

Clinical Trials

Clinical TrialsLearn More" title="" id="clinical-trials-info" class="drug-info-popup" href="javascript:void(0);">
Phase Status Purpose Conditions Count
4 Active Not Recruiting Treatment Metastatic Castration Resistant Prostate Cancer (CRPC) 1
4 Completed Treatment Metastatic Castration Resistant Prostate Cancer (CRPC) 2
4 Completed Treatment Prostate Cancer 2
4 Completed Treatment Refractory, metastatic hormone-refractory Prostate cancer 1
4 Recruiting Supportive Care Castration Resistant Prostatic Cancer/Hormone Refractory Prostate Cancer/Recurrent Prostate Carcinoma/Refractory, metastatic hormone-refractory Prostate cancer/Stage IV Prostate Cancer 1
4 Recruiting Treatment Castration Resistant Prostatic Neoplasms 1
4 Recruiting Treatment Metastatic Castration Resistant Prostate Cancer (CRPC) 1
4 Terminated Treatment Metastatic Castration Resistant Prostate Cancer (CRPC) 1
3 Active Not Recruiting Treatment Adenocarcinoma of the Prostate/Hormone Resistant Prostate Cancer/Prostate Cancer - Recurrent/Stage IV Prostate Cancer 1
3 Active Not Recruiting Treatment Castration Resistant Prostatic Neoplasms 1

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage Forms
Form Route Strength
Capsule Oral
Capsule Oral 40 mg/1
Tablet Oral 40 mg/1
Tablet Oral 80 mg/1
Tablet, film coated Oral 40 MG
Tablet, film coated Oral 80 MG
Capsule, liquid filled Oral 40 mg
Capsule Oral 40 mg
Capsule, liquid filled Oral 40.0 mg
Prices
Not Available
Patents
Patent Number Pediatric Extension Approved Expires (estimated) Region
US8183274 No 2012-05-22 2026-05-15 US flag
US9126941 No 2015-09-08 2026-05-15 US flag
US7709517 No 2010-05-04 2027-08-13 US flag

Properties

State
Solid
Experimental Properties
Property Value Source
melting point (°C) 201 ºC L43242
water solubility Insoluble FDA label
logP 3.0 L43242
Predicted Properties
Property Value Source
Water Solubility 0.00136 mg/mL ALOGPS
logP 3.75 ALOGPS
logP 4.16 Chemaxon
logS -5.5 ALOGPS
pKa (Strongest Acidic) 13.05 Chemaxon
pKa (Strongest Basic) -1.6 Chemaxon
Physiological Charge 0 Chemaxon
Hydrogen Acceptor Count 3 Chemaxon
Hydrogen Donor Count 1 Chemaxon
Polar Surface Area 76.44 Å2 Chemaxon
Rotatable Bond Count 4 Chemaxon
Refractivity 113.48 m3·mol-1 Chemaxon
Polarizability 42.69 Å3 Chemaxon
Number of Rings 3 Chemaxon
Bioavailability 1 Chemaxon
Rule of Five Yes Chemaxon
Ghose Filter Yes Chemaxon
Veber's Rule No Chemaxon
MDDR-like Rule No Chemaxon
Predicted ADMET Features
Property Value Probability
Human Intestinal Absorption + 0.9356
Blood Brain Barrier + 0.8514
Caco-2 permeable + 0.5219
P-glycoprotein substrate Non-substrate 0.7609
P-glycoprotein inhibitor I Inhibitor 0.6464
P-glycoprotein inhibitor II Inhibitor 0.5693
Renal organic cation transporter Non-inhibitor 0.899
CYP450 2C9 substrate Non-substrate 0.7447
CYP450 2D6 substrate Non-substrate 0.8061
CYP450 3A4 substrate Substrate 0.5589
CYP450 1A2 substrate Non-inhibitor 0.5613
CYP450 2C9 inhibitor Inhibitor 0.7126
CYP450 2D6 inhibitor Non-inhibitor 0.9148
CYP450 2C19 inhibitor Inhibitor 0.6882
CYP450 3A4 inhibitor Inhibitor 0.6184
CYP450 inhibitory promiscuity High CYP Inhibitory Promiscuity 0.6711
Ames test Non AMES toxic 0.683
Carcinogenicity Non-carcinogens 0.7232
Biodegradation Not ready biodegradable 1.0
Rat acute toxicity 2.4319 LD50, mol/kg Not applicable
hERG inhibition (predictor I) Weak inhibitor 0.9911
hERG inhibition (predictor II) Inhibitor 0.7079
ADMET data is predicted usingadmetSAR, a free tool for evaluating chemical ADMET properties. (23092397)

Spectra

Mass Spec (NIST)
Not Available
Spectra
Spectrum Spectrum Type Splash Key
Predicted MS/MS Spectrum - 10V, Positive (Annotated) Predicted LC-MS/MS Not Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated) Predicted LC-MS/MS Not Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated) Predicted LC-MS/MS Not Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated) Predicted LC-MS/MS Not Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated) Predicted LC-MS/MS Not Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated) Predicted LC-MS/MS Not Available
MS/MS Spectrum - , positive LC-MS/MS splash10-014i-0321900000-b1c610c4a717fdea030e

Targets

Build, predict & validate machine-learning models
Use our structured and evidence-based datasets tounlock new
insights and accelerate drug research.
Learn more
Use our structured and evidence-based datasets to unlock new insights and accelerate drug research.
Learn more
Details 1.Androgen receptor
Kind
Protein
Organism
Humans
Pharmacological action
Yes
Actions
Inhibitor
General Function
Zinc ion binding
Specific Function
Steroid hormone receptors are ligand-activated transcription factors that regulate eukaryotic gene expression and affect cellular proliferation and differentiation in target tissues. Transcription ...
Gene Name
AR
Uniprot ID
P10275
Uniprot Name
Androgen receptor
分子量
98987.9 Da
References
  1. FDA Approved Drug Products: Xtandi (enzalutamide) capsules/tablets for oral use 2022 [Link]

Enzymes

Details 1.Cytochrome P450 2C8
Kind
Protein
Organism
Humans
Pharmacological action
No
Actions
Substrate
Inhibitor
General Function
Steroid hydroxylase activity
Specific Function
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally un...
Gene Name
CYP2C8
Uniprot ID
P10632
Uniprot Name
Cytochrome P450 2C8
分子量
55824.275 Da
References
  1. Backman JT, Filppula AM, Niemi M, Neuvonen PJ: Role of Cytochrome P450 2C8 in Drug Metabolism and Interactions. Pharmacol Rev. 2016 Jan;68(1):168-241. doi: 10.1124/pr.115.011411. [文章]
  2. Poondru年代,Ghicavii V, Khosravan R, Manchandani P,Heo N, Moy S, Wojtkowski T, Patton M, Haas GP: Effect of enzalutamide on PK of P-gp and BCRP substrates in cancer patients: CYP450 induction may not always predict overall effect on transporters. Clin Transl Sci. 2022 May;15(5):1131-1142. doi: 10.1111/cts.13229. Epub 2022 Feb 4. [文章]
  3. Flockhart Table of Drug Interactions [Link]
  4. FDA Approved Drug Products: Xtandi (enzalutamide) capsules/tablets for oral use 2022 [Link]
Details 2.Cytochrome P450 3A4
Kind
Protein
Organism
Humans
Pharmacological action
No
Actions
Substrate
Inducer
General Function
6tamin d3 25-hydroxylase activity
Specific Function
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It performs a variety of oxidation react...
Gene Name
CYP3A4
Uniprot ID
P08684
Uniprot Name
Cytochrome P450 3A4
分子量
57342.67 Da
References
  1. Gibbons JA, de Vries M, Krauwinkel W, Ohtsu Y, Noukens J, van der Walt JS, Mol R, Mordenti J, Ouatas T: Pharmacokinetic Drug Interaction Studies with Enzalutamide. Clin Pharmacokinet. 2015 Oct;54(10):1057-69. doi: 10.1007/s40262-015-0283-1. [文章]
  2. FDA table of interactions [Link]
  3. Enzalutamide FDA label [Link]
  4. Flockhart Table of Drug Interactions [Link]
  5. FDA Drug Development and Drug Interactions: Table of Substrates, Inhibitors and Inducers [Link]
Details 3.Cytochrome P450 2C9
Kind
Protein
Organism
Humans
Pharmacological action
No
Actions
Inducer
General Function
Steroid hydroxylase activity
Specific Function
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally un...
Gene Name
CYP2C9
Uniprot ID
P11712
Uniprot Name
Cytochrome P450 2C9
分子量
55627.365 Da
References
  1. Golshayan AR, Antonarakis ES: Enzalutamide: an evidence-based review of its use in the treatment of prostate cancer. Core Evid. 2013;8:27-35. doi: 10.2147/CE.S34747. Epub 2013 Apr 4. [文章]
  2. Flockhart Table of Drug Interactions [Link]
  3. FDA Drug Development and Drug Interactions: Table of Substrates, Inhibitors and Inducers [Link]
  4. FDA Approved Drug Products: Xtandi (enzalutamide) capsules/tablets for oral use 2022 [Link]
  5. Enzalutamide FDA label [File]
  6. Xtandi Monograph [File]
Details 4.Cytochrome P450 2C19
Kind
Protein
Organism
Humans
Pharmacological action
No
Actions
Inducer
General Function
Steroid hydroxylase activity
Specific Function
Responsible for the metabolism of a number of therapeutic agents such as the anticonvulsant drug S-mephenytoin, omeprazole, proguanil, certain barbiturates, diazepam, propranolol, citalopram and im...
Gene Name
CYP2C19
Uniprot ID
P33261
Uniprot Name
Cytochrome P450 2C19
分子量
55930.545 Da
References
  1. Gibbons JA, de Vries M, Krauwinkel W, Ohtsu Y, Noukens J, van der Walt JS, Mol R, Mordenti J, Ouatas T: Pharmacokinetic Drug Interaction Studies with Enzalutamide. Clin Pharmacokinet. 2015 Oct;54(10):1057-69. doi: 10.1007/s40262-015-0283-1. [文章]
  2. Flockhart Table of Drug Interactions [Link]
  3. FDA Drug Development and Drug Interactions: Table of Substrates, Inhibitors and Inducers [Link]
  4. FDA Approved Drug Products: Xtandi (enzalutamide) capsules/tablets for oral use 2022 [Link]
  5. Ezalutamide FDA label [File]
Details 5.Cytochrome P450 2B6
Kind
Protein
Organism
Humans
Pharmacological action
No
Actions
Inhibitor
General Function
Steroid hydroxylase activity
Specific Function
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally un...
Gene Name
CYP2B6
Uniprot ID
P20813
Uniprot Name
Cytochrome P450 2B6
分子量
56277.81 Da
References
  1. Hutson PR: Enzalutamide: A Step Towards Pharmacokinetic-Based Dosing in Men with Metastatic Castration-Resistant Prostate Cancer. Clin Pharmacokinet. 2015 Oct;54(10):989-91. doi: 10.1007/s40262-015-0293-z. [文章]
  2. Poondru年代,Ghicavii V, Khosravan R, Manchandani P,Heo N, Moy S, Wojtkowski T, Patton M, Haas GP: Effect of enzalutamide on PK of P-gp and BCRP substrates in cancer patients: CYP450 induction may not always predict overall effect on transporters. Clin Transl Sci. 2022 May;15(5):1131-1142. doi: 10.1111/cts.13229. Epub 2022 Feb 4. [文章]
  3. FDA Approved Drug Products: Xtandi (enzalutamide) capsules/tablets for oral use 2022 [Link]
  4. Enzalutamide FDA Review [File]
Details 6.Cytochrome P450 3A5
Kind
Protein
Organism
Humans
Pharmacological action
No
Actions
Substrate
Inducer
General Function
Oxygen binding
Specific Function
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally un...
Gene Name
CYP3A5
Uniprot ID
P20815
Uniprot Name
Cytochrome P450 3A5
分子量
57108.065 Da
References
  1. FDA table of interactions [Link]
  2. Flockhart Table of Drug Interactions [Link]
  3. FDA Drug Development and Drug Interactions: Table of Substrates, Inhibitors and Inducers [Link]
  4. Health Canada Approved Drug Products: Xtandi (enzalutamide) capsules/tablets for oral use 2022 [Link]
  5. Xtandi monograph [File]

航空公司

Details 1.Serum albumin
Kind
Protein
Organism
Humans
Pharmacological action
No
Actions
Binder
General Function
Toxic substance binding
Specific Function
Serum albumin, the main protein of plasma, has a good binding capacity for water, Ca(2+), Na(+), K(+), fatty acids, hormones, bilirubin and drugs. Its main function is the regulation of the colloid...
Gene Name
ALB
Uniprot ID
P02768
Uniprot Name
Serum albumin
分子量
69365.94 Da
References
  1. FDA Approved Drug Products: Xtandi (enzalutamide) capsules/tablets for oral use 2022 [Link]

Transporters

Details 1.P-glycoprotein 1
Kind
Protein
Organism
Humans
Pharmacological action
No
Actions
Inhibitor
General Function
Xenobiotic-transporting atpase activity
Specific Function
Energy-dependent efflux pump responsible for decreased drug accumulation in multidrug-resistant cells.
Gene Name
ABCB1
Uniprot ID
P08183
Uniprot Name
Multidrug resistance protein 1
分子量
141477.255 Da
References
  1. Poondru年代,Ghicavii V, Khosravan R, Manchandani P,Heo N, Moy S, Wojtkowski T, Patton M, Haas GP: Effect of enzalutamide on PK of P-gp and BCRP substrates in cancer patients: CYP450 induction may not always predict overall effect on transporters. Clin Transl Sci. 2022 May;15(5):1131-1142. doi: 10.1111/cts.13229. Epub 2022 Feb 4. [文章]
  2. FDA Approved Drug Products: Xtandi (enzalutamide) capsules/tablets for oral use 2022 [Link]

Drug created at June 05, 2013 05:12 / Updated at November 10, 2022 05:47